leisure time -WSS

leisure time

author：focus 2025-09-06 03:25:57 - browse：7565

Miniature people figurines standing in a group looking down. -- health tech coverage from STAT — Adobe

In less than two years, digital health’s high-flying class of public debuts have landed with a resounding thud.

Accelerated by the pandemic’s forced adoption of telehealth and other digital health solutions, 2021 saw more than 30 health technology startups go public, raising hundreds of millions and in some cases billions of dollars. Today, three members of the class of 2021 have gone bankrupt. Twelve companies have lost more than 90% of their initial value, including Bright Health Group, Cue Health, and Better Therapeutics. And dangerously low reserves have inspired desperate moves to slash costs, drum up liquidity, and find buyers.

Most recently, the bankruptcy of digital primary care company Babylon Health has drawn attention to the plight of newly-public health tech companies, and how the froth of dealmaking at the height of the pandemic led to overblown valuations. Before its debut in June 2021, Babylon was valued at $4.2 billion; after filing for bankruptcy in August, its U.K. telemedicine business was sold for just over $600,000.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Congress: Prevent baby formula shortages by passing a new bill

hotspot

leisure time

WSS

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

Asahi Kasei to buy Calliditas, picking up kidney disease drug

FDA clears Verve to begin U.S. study of gene

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Protect nursing home residents from future pandemics

The world needs the new pandemic treaty

entertainment

leisure time

knowledge

Drug repurposing or repositioning? The language matters

Why we need mandatory labeling of GMO products

Malaria cases in Florida and Texas: Here’s what you need to know

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Duchenne breakthrough therapy leaves behind pioneering families

FDA clears Verve to begin U.S. study of gene

The high cost of giving birth even with insurance

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

focus

Protect nursing home residents from future pandemics

FDA clears Verve to begin U.S. study of gene

Protect nursing home residents from future pandemics

Is there really a nursing shortage in the U.S.?

Questions loom on AstraZeneca cancer drug as safety concerns ebb

FDA clears Verve to begin U.S. study of gene

hotspot

Wikipedia

leisure time

hotspot